No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
On Jun. 5, 2020, the Chief Investigators of the randomised evaluation of COVid-19 thERapY (RECOVERY) trial on hydroxychloroquine…
Sorrento announced COVIDTRAP(STI-4398) demonstrated in preclinical studies its ability to completely inhibit SARS-CoV-2 viral infection In vitro
On Jun. 5, 2020, Sorrento announced it had completed a preclinical batch of the STI-4398 (COVIDTRAP) protein and…
ViralClear added St David’s HealthCare to phase II trial for broad-spectrum oral anti-viral COVID-19 candidate
On Jun. 5, 2020, BioSig Technologies and its subsidiary, ViralClear Pharma, announced it had expanded its patient enrollment…
University of Queensland, CEPI and CSL partnered to advance development of COVID-19 vaccine candidate
On Jun. 5, 2020, CEPI, the Coalition for Epidemic Preparedness Innovations, CSL and The University of Queensland (UQ)…
World leaders made historic commitments to provide equal access to vaccines for all
On Jun. 4, 2020, world leaders pledged an additional US$ 8.8 billion for Gavi, the Vaccine Alliance, far…
HHS announced new laboratory data reporting guidance for COVID-19 testing
On Jun. 4, 2020, the U.S. Department of Health and Human Services (HHS) announced new Guidance that specified…
The Gates Foundation pledged $16 billion to Gavi, the Vaccine Alliance, to protect the next generation with vaccines
On Jun. 4, 2020, the Bill & Melinda Gates Foundation announced a five-year, US$1.6 billion commitment to Gavi,…
AstraZeneca announced next steps towards broad and equitable access to Oxford Universitys COVID-19 vaccine
On Jun. 4, 2020, AstraZeneca announced the next steps in its commitment to broad and equitable global access…
Introduction and spread of SARS-CoV-2 in the greater Boston area
On Jun. 4, 2020, data from the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and the…
Novavax awarded Department of Defense contract for COVID-19 vaccine
On Jun. 4, 2020, Novavax announced that the company had been awarded a contract by the U.S. Department…
INOVIO and IVI Partnered with Seoul National University Hospital to start phase 1/2 clinical trial of COVID-19 DNA vaccine (INO-4800) in South Korea
On Jun. 4, 2020, INOVIO and Seoul National University Hospital announced a partnership to start a Phase 1/2…
iBio announced second COVID-19 vaccine program
On Jun. 4, 2020, iBio announced it had initiatied preclinical immunization studies for its second COVID-19 vaccine platform….
Virginia Tech researchers established a reverse genetics system to facilitate COVID-19 research
On Jun. 4, 2020, with funding from the Fralin Life Sciences Institute at Virginia Tech, researchers James Weger-Lucarelli…
Roche initiated initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
On Jun. 4, 2020, Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA)…
CEPI granted $141 million to consortium of Bharat Biotech and IVI to advance development of Chikungunya vaccine in collaboration with Ind-CEPI
On Jun. 3, 2020, CEPI, the Coalition for Epidemic Preparedness Innovations, in collaboration with Ind-CEPI, announced a new…
NIH reported early results show benefit of remdesivir for COVID-19
On Jun. 2, 2020, the NIH reported that early results showed that remdesivir benefited hospitalized patients with severe…
FDA cleared IND for iNKT Cells to treat COVID-19 patients
On Jun. 2, 2020, Agenus announced the FDA’s clearance of AgenTus’ IND application for an allogeneic iNKT therapy….
The USDA announced the first confirmed case of a dog in the US to test positive for SARS-CoV-2
On Jun. 2, 2020, the USDA announced the first confirmed case of SARS-CoV-2 (the virus that causes COVID-19)…
Albert Einstein College of Medicine awarded $1 million for COVID-19 research from the Price Family Foundation
On Jun. 2, 2020, Albert Einstein College of Medicine announced it had received a $1 million challenge grant…
Trevena announced collaboration with Imperial College London to evaluate TRV027 in COVID-19 patients
On Jun. 2, 2020, Trevena announced it had entered into a collaboration with Imperial College London to evaluate…
Resverlogix announced COVID-19 clinical trial program launch
On Jun. 1, 2020, Resverlogix announced that it is moving forward with a plan to further evaluate apabetaloneï¾’s…
Cytiva and Entos Pharmaceuticals work together to accelerate development of COVID19 vaccines
On Jun. 1, 2020, Entos Pharmaceuticals announced a partnership with Cytiva, formerly part of GE Healthcare Life Sciences….
The US Dept of Defense launched effort to collect COVID-19 convalescent plasma
On Jun. 1, 2020, U.S. Dept. of Defense announced it had begun an effort to collect 8,000 donated…
Gilead announced results from phase 3 trial of Remdesivir in patients with moderate COVID-19
On Jun. 1, 2020, Gilead Sciences announced topline results from the Phase 3 SIMPLE trial in hospitalized patients…
Emergent BioSolutions joined U.S. Government’s Warp Speed Program for COVID-19 vaccine development and manufacturing
On Jun. 1, 2020, Emergent BioSolutions announced it had been issued a task order under an existing contract…
Anixa Biosciences and OntoChem synthesized four potential Covid-19 drugs for testing in biological assays
On Jun. 1, 2020, Anixa Biosciences and OntoChem announced they had synthesized four potential Covid-19 compounds that will…
Eli Lilly began world’s first study of a potential COVID-19 antibody treatment in humans
On Jun. 1, 2020, Eli Lilly announced patients had been dosed in the world’s first study of a…
Proteostasis Therapeutics announced in vitro data for PTI-129 as potential treatment candidate for COVID-19
On Jun. 1, 2020, Proteostasis Therapeutics announced results from in vitro studies evaluating the use of PTI-129 as…
FDA issued Emergency Use Authorization for Impella RP as therapy for COVID-19 patients with right heart failure
On Jun. 1, 2020, the FDA issued an emergency use authorization (EUA) for Impella RP to include patients…
Altimmune launched clinical trial of T-COVIDTM, an investigational intranasal immune modulator for treatment of patients with early COVID-19
On Jun. 1, 2020, Altimmune announced the FDA had authorized the Company to proceed with a clinical trial…